Druggable Antibacterial Targets and Bactericidal Compounds

Eurofarma is a Brazilian multinational pharmaceutical company engaged in biopharmaceuticals. Eurofarma is currently seeking validated targets, novel compounds, and/or adjuvant compounds for antibacterial drugs/therapies.

Approaches of Interest

• The highest priority is given to opportunities involving validated targets and small molecule drugs, synthetics and natural products are also within scope, but there is less interest in peptide-based approaches
• Priority will be given to bactericidal compounds, however, bacteriostatic and adjuvant compounds are also of some interest
• There is a particular interest in approaches that target Gram‑negative bacteria and ESKAPE pathogens, or other bacterial pathogens related to antimicrobial resistance
• Opportunities targeting mycobacteria are out of the scope of this campaign
• There is an interest in molecules with specific pathogen activities as well as broad‑spectrum antibiotics
• Antibiotic discovery platforms are also of interest

Validation

• Opportunities validated beyond efficacy, such as those supported by physicochemical and pharmacokinetic data e.g. ADME, and those with in vivo data, are of the highest priority
• Well‑established, repeatable, biochemical and cell‑based assays are preferred
• Assays requiring significant further development from Eurofarma are out of the scope of this campaign

Developmental Stages of Interest

• Eurofarma is open to approaches from the discovery stage through to candidate selection, with a particular interest in opportunities with proof‑of‑concept data and beyond

Submission Information

Submission of one page, 200-300 word briefs are encouraged. Along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Eurofarma is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Co‑development is an ideal scenario, but Eurofarma is very flexible with collaboration. IP and Royalties will be discussed on a project basis.